Neurology · Los Angeles area, CA
Neurology studies in Los Angeles area, CA
114 recruiting studies have a site in the Los Angeles area. This page includes nearby cities such as Santa Monica, Beverly Hills, Pasadena, Long Beach.
114 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Los Angeles, CA + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Anaheim, CA + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Carlsbad, CA + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Downey, CA + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.
- Location
- Anaheim, CA + 22 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Irvine, CA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Anaheim, CA + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Anaheim, CA + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Anaheim, CA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Corxel Pharmaceuticals
- Location
- Long Beach, CA + 19 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Irvine, CA + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Orange, CA + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Arcadia, CA + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Anaheim, CA + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Los Angeles, CA + 13 other US sites
- Eligibility basics
- Ages 50–80
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Irvine, CA + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Irvine, CA + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Colton, CA + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Orange, CA + 7 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma
- Location
- Orange, CA + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1/Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron Pharmaceuticals
- Location
- Los Angeles, CA + 8 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- La Jolla, CA + 39 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.